Mafenide

Mafenide

SCHEMBL41628

NCc1ccc(S(N)(=O)=O)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

folP

The experimentally established mechanism targets of Mafenide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CA2 P00918 18/20 1.00
CA1 P00915 11/20 1.00
CA12 O43570 10/20 1.00
CA9 Q16790 10/20 1.00
CA14 Q9ULX7 6/20 1.00
CA4 P22748 5/20 1.00
CA6 P23280 5/20 1.00
CA5A P35218 5/20 1.00
CA7 P43166 5/20 1.00
CA5B Q9Y2D0 5/20 1.00
MAPT P10636 1/20 0.95
SMN1; SMN2 Q16637 2/20 0.77
KDM4E B2RXH2 1/20 0.77
PSIP1 O75475 1/20 0.61
USP2 O75604 1/20 0.54
TSHR P16473 1/20 0.54
CA13 Q8N1Q1 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
AGO2 Q9UKV8 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Mafenide SCHEMBL9295695 1.00 CA2 (1.00) CA2CA1CA12CA9CA14
Mafenide SCHEMBL1203324 0.98 CA2 (1.00) CA2CA1CA12CA9CA14
Mafenide SCHEMBL425524 0.98 CA2 (1.00) CA2CA1CA12CA9CA14
Mafenide SCHEMBL686407 0.95 CA2 (0.95) CA2CA1CA12CA9CA14
Mafenide SCHEMBL2934434 0.95 CA2 (0.91) CA2CA1CA12CA9CA14
Mafenide SCHEMBL27294054 0.93 CA2 (0.87) CA2CA1CA12CA9CA14
Mafenide SCHEMBL1072130 0.93 CA2 (0.87) CA2CA1CA12CA9CA14
Mafenide SCHEMBL11664949 0.91 CA2 (0.83) CA2CA1CA12CA9CA14
Mafenide SCHEMBL27599824 0.89 KDM4E (0.82) CA2CA1CA12CA9CA14
Mafenide SCHEMBL41627 0.88 SMN1; SMN2 (1.00) CA2CA1CA12CA9CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 15960 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260108619-A1 CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS HANGZHOU DAC BIOTECH CO., LTD. (CN) 2026-04-23 US claimed
US-20260090584-A1 SYSTEMS AND METHODS FOR ESTIMATING AEROSOLIZATION EMISSION SCIENTIFIC HORIZONS CONSULTING LLC (US) 2026-04-02 US claimed
US-20260091119-A1 ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF GLIOMA CELLIS AG (CH) 2026-04-02 US claimed
US-12576124-B2 Formulation of a conjugate of a tubulysin analog to a cell-binding molecule HANGZHOU DAC BIOTECH CO., LTD (CN) 2026-03-17 US claimed
US-20260027140-A1 COMPOSITIONS AND METHODS FOR TREATING AND AMELIORATING RESPIRATORY CONDITIONS AND INFLAMMATION OF MUCOSA ATOPIC MEDICAL INC (US) 2026-01-29 US claimed
US-20260027255-A1 Cross-Linked Telechelic Polymer Compositions, Methods of Preparation Thereof, and Methods of Using Same BETTY YU SKIN TECH ADVISORS LLC (US) 2026-01-29 US claimed
US-20260000678-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH PSEUDO-ALLERGIC REACTION TAKASAKI UNIV OF HEALTH AND WELFARE (JP) 2026-01-01 US claimed
US-12465623-B2 Use of parasites and extracellular vesicles obtained from parasites in cancer treatment YEDITEPE UNIVERSITESI (TR) 2025-11-11 US claimed
US-20250339551-A1 AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) 2025-11-06 US claimed
EP-4642484-A1 TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE Hangzhou Seehe Biotechnology Co., Ltd (CN) 2025-11-05 EP claimed
US-4454128-A ANTIBIOTICS DR. KARL THOMAE GMBH (DE) 1984-06-12 US claimed
US-4447422-A Penicillins and compositions containing them BEECHAM GROUP P.1.C. (GB) 1984-05-08 US claimed
EP-0035161-B1 CEPHALOSPORINS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS Dr. Karl Thomae GmbH (DE) 1983-11-23 EP claimed
US-4393048-A ALGINATE, GLYCERINE, WATER THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) 1983-07-12 US claimed
US-4370327-A Cephalosporins and pharmaceutical compositions BOEHRINGER INGELHEIM GMBH (DE) 1983-01-25 US claimed
EP-0067610-A1 Penicillins, a process for their preparation and compositions containing them BEECHAM GROUP PLC (GB) 1982-12-22 EP claimed
US-4169763-A OF A CORYNEBACTERIA RESISTANT TO ASPARTIC ACID ANALOGS AND SULFA DRUGS KYOWA HAKKO KOGYO CO., LTD. (JP) 1979-10-02 US claimed
US-4156737-A P-Aminomethyl-benzene-sulfonamide derivatives, process for their preparation and applications thereof SEUREF A.G. (LI) 1979-05-29 US claimed
US-4122158-A FOR TREATMENT OF BURNS; BIODEGRADABLE HYDROPHOBIC POLYMER; SUSTAINED RELEASE ALZA CORPORATION (US) 1978-10-24 US claimed
US-3983209-A HYDROPHOBIC BIOERODIBLE POLYMER, MICROBIOCIDE OR PROTEOLYTIC ENZYME ALZA CORPORATION (US) 1976-09-28 US claimed